0 CHECKOUT

VERTEX , Positive Investment Alert - HCV/HIV Co-Infection – An Untapped Opportunity!

  • ID: 1948434
  • October 2011
  • MP Advisors
1 of 4

Vertex (VRTX) next target is to capture the HCV/HIV co-infected patients and gain greater HCV market through shorter duration and dosing advantage to a niche pts population of IL28B CC Genotype. We expect most of the near term milestones related to Earnings, Rheumatoid Arthritis (RA), Cystic Fibrosis (CF), etc. programs to have a positive impact on the stock price. For more details, please read our report released on 25th October, 2011 on VRTX titled “HCV/HIV Co-Infection – An Untapped Opportunity!”

Note: Product cover images may vary from those shown
2 of 4

- Cystic Fibrosis
- HCV/HIV Co-Infection
- HCV Pipeline
- Incivek
- Interferon free HCV drug
- Vertex
- VX-509
- VX-770
- VX-809
- Victrelis

Note: Product cover images may vary from those shown
3 of 4

- Cystic Fibrosis
- HCV/HIV Co-Infection
- HCV Pipeline
- Incivek
- Interferon free HCV drug
- Vertex
- VX-509
- VX-770
- VX-809
- Victrelis

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Db

Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.